Context Therapeutics nominates CTIM-76 as lead CLDN6 bispecific; IND expected Q1 2024

Context Therapeutics Inc.

CTIM-76 is a CLDN6 x CD3 bispecific antibody with silenced Fc to reduce aberrant T-cell activation.
IND submission for CTIM-76 planned for Q1 2024 to the FDA.
Targets CLDN6-positive solid tumors including ovarian, endometrial, testicular, and gastric cancers.
Preclinical data show potent lysis of CLDN6+ cancer cells with minimal free cytokine release.
Collaboration with Integral Molecular; webinar on December 1, 2022, at 11 a.m. ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.